Exponent (EXPO) to Post Quarterly Earnings on Thursday

Exponent (NASDAQ:EXPO) is expected to be releasing its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to post earnings of $0.55 per share and revenue of $144.9890 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Exponent (NASDAQ:EXPO) last announced its quarterly earnings results on Thursday, April 30th. The business services provider reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.56 by $0.03. Exponent had a net margin of 18.07% and a return on equity of 27.94%. The firm had revenue of $166.30 million during the quarter, compared to analysts’ expectations of $149.53 million. During the same quarter last year, the company posted $0.52 earnings per share. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. On average, analysts expect Exponent to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Exponent Price Performance

Shares of EXPO opened at $62.76 on Tuesday. The company has a market cap of $3.04 billion, a PE ratio of 29.19 and a beta of 0.72. The firm has a 50-day moving average of $59.36 and a 200-day moving average of $65.42. Exponent has a one year low of $51.91 and a one year high of $81.95.

Exponent Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Investors of record on Friday, June 5th were paid a $0.31 dividend. This represents a $1.24 annualized dividend and a yield of 2.0%. The ex-dividend date was Friday, June 5th. Exponent’s dividend payout ratio (DPR) is 57.67%.

Insider Activity at Exponent

In related news, CEO Catherine Corrigan sold 4,194 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $54.06, for a total value of $226,727.64. Following the transaction, the chief executive officer owned 105,218 shares in the company, valued at approximately $5,688,085.08. This represents a 3.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Joseph Sala sold 2,066 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $56.66, for a total value of $117,059.56. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 15,324 shares of company stock valued at $855,019 over the last three months. Company insiders own 1.60% of the company’s stock.

Institutional Trading of Exponent

Several hedge funds have recently added to or reduced their stakes in EXPO. Quantinno Capital Management LP grew its holdings in Exponent by 44.1% in the 2nd quarter. Quantinno Capital Management LP now owns 4,872 shares of the business services provider’s stock valued at $364,000 after buying an additional 1,490 shares in the last quarter. WINTON GROUP Ltd acquired a new stake in shares of Exponent during the fourth quarter worth $361,000. Corient Private Wealth LLC boosted its position in shares of Exponent by 57.0% in the second quarter. Corient Private Wealth LLC now owns 4,793 shares of the business services provider’s stock valued at $358,000 after acquiring an additional 1,741 shares during the period. Brevan Howard Capital Management LP bought a new stake in shares of Exponent in the third quarter valued at about $324,000. Finally, PDT Partners LLC acquired a new position in shares of Exponent in the fourth quarter valued at about $294,000. 92.37% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Exponent in a research report on Friday, July 17th. JPMorgan Chase & Co. cut their price objective on Exponent from $95.00 to $80.00 and set an “overweight” rating for the company in a research report on Friday, May 15th. Finally, UBS Group reiterated a “neutral” rating and set a $75.00 target price on shares of Exponent in a research note on Tuesday, June 2nd. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $77.50.

Exponent Company Profile

Exponent, Inc (NASDAQ: EXPO) is an engineering and scientific consulting firm that offers multidisciplinary analysis and advisory services to clients across a range of industries. The company’s expertise spans mechanical, materials and corrosion engineering, civil and structural engineering, electrical engineering, industrial hygiene, toxicology and health sciences, and failure analysis. Exponent provides support for product design, performance evaluation, litigation consulting, and regulatory compliance, helping manufacturers, insurers, law firms and government agencies address complex technical challenges.

Founded in 1967 in Menlo Park, California, Exponent has grown from a small failure-analysis laboratory into a global consulting practice.